PRESS-RELEASE filed Jun 15, 2026 at 06:50 ET
Pharvaris presented positive Phase 3 RAPIDe-3 data at EAACI 2026, showing deucrictibant achieved a median time to onset of symptom relief of 1.28 hours vs >12 hours for placebo, and median time to complete resolution of 11.95 hours vs >48 hours. The majority of attacks (83.0%) were treated with a single capsule, and 93.2% required no rescue medication. Long-term prophylaxis data from CHAPTER-1 OLE showed ~92% reduction in attack rates and 100% of participants reporting well-controlled disease. The company is preparing NDA submission for on-demand treatment and expects topline data from the pivotal CHAPTER-3 prophylaxis study in Q3 2026.